Fig. 6 | Scientific Reports

Fig. 6

From: Enhanced efficacy of combined VEGFR peptide–drug conjugate and anti-PD-1 antibody in treating hepatocellular carcinoma

Fig. 6

Effects of QR-KLU combined with anti-PD-1 antibody on the necrosis and proliferation of subcutaneous Hepa1–6 liver tumors in mice (n = 6). (A) Necrosis and proliferation of subcutaneous Hepa1–6 liver tumors in each group of mice (N: tumor necrotic area; T: tumor nonnecrotic area). (B) Evaluation of the cumulative survival time of tumor-bearing mice in each group using Kaplan–Meier curve. PD-1 programmed cell death receptor-1, QR-KLU peptide (QR)–drug (KLU) conjugate.

Back to article page